Teva gets Copaxone nod in Japan; India's Dishman in manufacture license deal on Sirturo;

> Japan's Takeda Pharmaceutical will handle sales of Copaxone on behalf of Teva ($TEVA) after the Israel-based company won Ministry of Health, Labour and Welfare approval for the multiple sclerosis drug in a once-daily 20-mg injection. Copaxone, or glatiramer acetate, was developed as an Unapproved New Drug by Teva Pharmaceutical K.K., a wholly owned subsidiary of Teva, at the request of the MHLW, according to a press release. "In March, 2013, Takeda and Teva signed an agreement in which Teva granted Takeda the right to commercialize the therapy in Japan." Release

> India's Dr. Reddy's Laboratories ($RDY) will buy the IP rights to anticoagulant fondaparinux from Alchemia for INR1.16 billion ($17.5 million), Livemint reported. The deal followed a payment of $1.15 million for its share of net profit from U.S. sales in the previous quarter. The Hyderabad, India-based company said fondaparinux earned $340 million in revenues in the year ended March 31. Report

> Australia's Benitec Biopharma ($BNTC) said Peter French, CEO and managing director, was invited to discuss Benitec's ddRNAi technology at The Cambridge Healthtech Institute's 13th Annual Discovery on Target Conference in Boston. The dual-listed company is in a Phase I/IIa trial of TT-034 aimed at treating hepatitis C by reducing its viral load. Release

> Japan's Eisai and U.S.-listed Arena Pharmaceuticals ($ARNA) plan two presentations on Belviq (lorcaserin HCl). The first is slated to start at the Annual Meeting of the American College of Clinical Pharmacology in San Francisco in late September while the second will take place in early October at the American Society of Bariatric Physicians meeting in Washington, DC. Release

> U.S.-based biotech RXi Pharmaceuticals ($RXII) was granted a patent from China's State Intellectual Property Office for candidate RXI-109 and related compounds aimed at the treatment of fibrotic disorders, including skin fibrosis, the company said in a release, adding that the patent is scheduled to expire in 2031. Release

> India's Dishman Pharmaceuticals and Chemicals said that it holds a license agreement from Johnson & Johnson ($JNJ) unit Janssen to manufacture the API of multidrug-resistant tuberculosis drug Sirturo (bedaquiline) at its facility in Bavla, India. Release

> China's Hongene Biotechnology has signed a strategic license agreement with U.S.-listed Marina Biotech to provide exclusive right to develop, supply and commercialize certain oligonucleotide constructs using Marina's Conformationally Restricted Nucleotide (CRN) chemistry in return for royalties. Hongene will also supply CRN-based oligonucleotides to Marina for commercial sales and drug development purposes. Release (PDF)

> Japan's Hitachi and Tokyo's Keio University are developing new ways to use artificial intelligence to detect disease signs via a pilot program that reviewed 45,000 employees who had poor checkup results and identified 50 employees who could benefit from immediate guidance on their health as part of insurance cost-saving efforts. Report

> India's Dr. Reddy's Laboratories has started sales of generic Nexium in the U.S., biting into the original AstraZeneca ($AZN) heartburn drug that had sales of $5.2 billion in the U.S. in the year ended July 2015, according to a report that cited figures from IMS Health. Report

> Chinese investors were key to funding Minnesota-based Ativa Medical of Minneapolis to the tune of $15 million in a B round as the company moves to develop its Ativa micro lab device for blood tests that can return results in minutes. Release

> Taiwan's over-the-counter drug instructions fail to explain the properties of products sold or provide information on ingredients used, the Taiwan Health Reform Foundation said in a call for changes by the regulator to work with companies on clearer standards. Report

> China distribution of Unyvero Systems and related units for detecting bacteria, fungi and antibiotic-resistance genes from Germany's Curetis will be handled by Beijing Clear Biotech, which will also be responsible for obtaining approvals in Greater China, the German company said in a news release. Curetis will retain all licenses and make trial initiation and approval milestone payments to Beijing Clear in return for specified minimum purchases of Unyvero Systems and related equipment annually. Release (PDF)